Pacira Biosciences, Inc. - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 15, 2013, by Pacira Pharmaceuticals, Inc. (now Pacira Biosciences, Inc.). The filing provides preliminary estimated financial results for the quarter and year ended December 31, 2012, in connection with a proposed private placement of convertible senior notes. The company is a biopharmaceutical firm focused on the commercialization of its product EXPAREL.
Key Financial Metrics
The following metrics are preliminary estimates provided by management and have not been audited:
- Quarter Ended Dec 31, 2012: Total revenues estimated at $10.5 million; EXPAREL net sales estimated at $7.8 million.
- Year Ended Dec 31, 2012: Total revenues estimated at $39.1 million; EXPAREL net sales estimated at $14.6 million.
- Liquidity: Cash, cash equivalents, restricted cash, and short-term investments estimated at $42.6 million as of December 31, 2012.
- Profitability, Margins, and Debt: The filing text does not provide clear values for net income, operating margins, or specific debt obligations other than the proposed $100 million convertible note offering.
Material Changes vs. Prior Period
Revenue growth is significant compared to the prior year:
- Quarter-over-Quarter: Total revenues increased from $4.2 million in Q4 2011 to an estimated $10.5 million in Q4 2012.
- Year-over-Year: Total revenues increased from $15.7 million in 2011 to an estimated $39.1 million in 2012.
- Drivers: Growth is primarily attributed to EXPAREL sales following its April 2012 launch and increased collaborative licensing revenue from the recognition of deferred revenue due to terminated license agreements.
- Sales Velocity: Average daily box sales of EXPAREL increased month-over-month from September to December 2012 by approximately 13%, 23%, 26%, and 39%, respectively. Total boxes sold from launch through December 31, 2012, were estimated at 5,497.
Guidance, Outlook, and Risks
Capital Markets Activity: The company announced an intention to offer $100 million in aggregate principal amount of convertible senior notes due 2019, with an option for an additional $10 million, subject to market conditions.
Forward-Looking Statements: The financial data presented is unaudited and subject to change pending finalization. The company cautions that actual results may differ materially due to risks including market acceptance of EXPAREL, manufacturing capabilities, and general economic conditions.
Risk Factors: Updated risk factors are included as Exhibit 99.2, referencing risks from the 2011 10-K and 2012 10-Q filings.
Investor Verification Checklist
- Verify the final audited financial statements for the year and quarter ended December 31, 2012, once released, as current figures are preliminary estimates.
- Confirm the successful completion and terms of the proposed $100 million convertible senior notes private placement.
- Monitor the continued month-over-month growth rate of EXPAREL daily box sales to validate commercialization momentum.
- Review the updated Risk Factors (Exhibit 99.2) for specific details on regulatory and market risks.